Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279092 · ClinicalTrials.gov registry record · Phase 2
Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study
A Phase 2 study of Total Knee Replacement and Knee Arthroplasty, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 2
- Study locations
NCT05279092 is a Phase 2 study of Total Knee Replacement and Knee Arthroplasty that is actively recruiting participants, run by Yale University. The registered enrollment target is 250 participants, above the 188-participant average among 9 other Total Knee Replacement trials with a reported enrollment target (33% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT05279092, a Phase 2 study of Total Knee Replacement and Knee Arthroplasty, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB.
Conditions Studied
Interventions
- DRUG Bupivacaine-Liposomal Bupivacaine
- DRUG Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Study Locations (2)
Connecticut
- Yale New Haven Hospital Saint Raphael Campus - New Haven
- Yale New Haven Hospital York Street Campus - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279092
The ClinicalTrials.gov registry entry for NCT05279092 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 188-participant average among 9 other Total Knee Replacement trials with a reported enrollment target (33% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Total Knee Replacement appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine-Liposomal Bupivacaine is the first listed.
NCT05279092 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05279092 about?
NCT05279092 is a clinical study titled "Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study". The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control amon...
What is the current status of trial NCT05279092?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-09-08. Estimated completion is 2028-03.
What conditions does trial NCT05279092 study?
This clinical trial studies the following conditions: Total Knee Replacement, Knee Arthroplasty.
What interventions are being tested in trial NCT05279092?
The interventions under investigation include: Bupivacaine-Liposomal Bupivacaine (DRUG), Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (DRUG).
Who is sponsoring clinical trial NCT05279092?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279092 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Total Knee Replacement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2
RECRUITING · Phase 2
-
Adductor Canal Block
ACTIVE NOT RECRUITING · Phase 2
-
An Open Label Data Collection Study of My Connect Post-Op, a Post-Operative Communication Tool
RECRUITING
-
Knee Arthroplasty Activity Trial
ACTIVE NOT RECRUITING · NA
-
Metal Ion Concentrations After Total Knee Arthroplasty
ACTIVE NOT RECRUITING
-
Antibiotic Elution in Total Knee Arthroplasty
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.